The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Targeting the CD73-adenosine axis in immuno-oncology
Open accessAbstract
The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the breakdown of extracellular ATP into adenosine. As such, they constitute critical components of the extracellular purinergic pathway and play important roles in maintaining tissue and immune homeostasis. With the coming of age of cancer immunotherapy, ectonucleotidases and adenosine receptors have emerged as novel therapeutic targets to enhance antitumor immune responses. With early-phase clinical trials showing promising results, it is becoming increasingly important to decipher the distinct mechanisms-of-action of adenosine-targeting agents, identify patients that will benefit from these agents and rationally develop novel synergistic combinations. Given the broad expression of ectonucleotidases and adenosine receptors, a better understanding of cell-specific roles will also be key for successful implementation of this new generation of immuno-oncology therapeutics. We here review the latest studies on the roles of CD73 and adenosine in cancer with a focus on cell-specific function. We also discuss ongoing clinical trials and future avenues for adenosine-targeting agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TGF-β-induced epithelial to mesenchymal transition
Xu, J., Lamouille, S., & Derynck, R. (2009) · Cell Research · doi:10.1038/cr.2009.5 · Cited by 2,804
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Self-citationMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Chalmin, F., Mignot, G., Bruchard, M., Chevriaux, A., Végran, F., Hichami, A., Ladoire, S., Derangère, V., Vincent, J., Masson, D., et al. (2012) · Immunity · doi:10.1016/j.immuni.2011.12.019 · Cited by 338
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Sitkovsky, M. V., Hatfield, S., Abbott, R., Belikoff, B., Lukashev, D., & Ohta, A. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0075 · Cited by 215
Cited by
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Self-citationHorvath, L., Thienpont, B., Zhao, L., Wolf, D., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 283
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Vau, N., Scarpelli, M., Cheng, L., & Montironi, R. (2021) · Cancers · doi:10.3390/cancers13010131 · Cited by 279
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
Metadata
- Authors
- Allard, D., Chrobak, P., Allard, B., Messaoudi, N., & Stagg, J.
- Venue
- Immunology Letters
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 205
- Pages
- 31-39
- ISSN
- 0165-2478 (ISSN-L)
- OpenAlex
- W2804816658
- Cited by
- 158
- References
- 10
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the CD73-adenosine axis in immuno-oncology. https://app.cochat.ai/papers/10.1016/j.imlet.2018.05.001
- The paper
- Allard, D., Chrobak, P., Allard, B., Messaoudi, N., & Stagg, J. (2019). Targeting the CD73-adenosine axis in immuno-oncology. Immunology Letters. https://doi.org/10.1016/j.imlet.2018.05.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.